Actively Recruiting
The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository
Led by Vanderbilt-Ingram Cancer Center · Updated on 2024-11-22
800
Participants Needed
1
Research Sites
578 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will investigate the association between clonal hematopoiesis and other conditions. Clonal hematopoiesis (CH) refers to the mutations in a person's stem cells which commonly affect people as they get older. These mutations have notably been linked to increased risk of certain cancers as well as increased risk of heart disease.
CONDITIONS
Official Title
The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient aged 18 years or older at time of consent
- Able to provide informed consent
- Diagnosed with idiopathic cytopenia (ICUS), idiopathic cytoses, clonal cytopenia of undetermined significance (CCUS), clonal hematopoiesis of indeterminate potential (CHIP), or at higher risk for clonal hematopoiesis (e.g., solid tumors or cardiovascular disease)
You will not qualify if you...
- Unable to provide informed consent
- Active diagnosis of hematologic malignancy such as CMML, AML, MDS, or MPN
- History of hematologic malignancy is allowed if in complete remission (e.g., previous myeloma or lymphoma)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, United States, 37203
Actively Recruiting
Research Team
V
Vanderbilt-Ingram Services for Timely Access
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here